Opinion|Videos|January 21, 2025
ASH 2024 Updates: Evaluating Potential Frontline Triplet Regimen: Pirtobrutinib Plus Venetoclax Plus Obinutuzumab in TN CLL
Panelists discuss how pirtobrutinib plus venetoclax and obinutuzumab shows promise as a frontline chronic lymphocytic leukemia (CLL) treatment option, with its high selectivity and favorable safety profile potentially offering advantages over current Bruton tyrosine kinase inhibitor–based regimens, though more long-term data is needed to determine its optimal place in therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Another frontline triplet regimen being studied is how pirtobrutinib plus venetoclax and obinutuzumab. What are your thoughts on this combination, and do you foresee a place in therapy for it in the frontline setting?
Advertisement
Related to this article
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5